Recent Updates
Recently added Catalysts
MANE Positive Sentiment

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Tuesday, November 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Veradermics reported third-quarter 2026 financial results and highlighted clinical progress on VDPHL01. The dermatologist-founded company advanced this potential treatment for pattern hair loss in men and women. Management described the year as defining for the firm's development pipeline. The update covered both financial performance and recent corporate milestones.

Market Sentiment Analysis

POSITIVE FACTORS

  • Veradermics reported strong financial results for Q3 2026.
  • The company advanced the development of VDPHL01.
  • Focus on innovative therapeutics for pattern hair loss.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+59%
120-day peak, hindsight
Typical move
10.4%
average across 2 past catalysts
Cash runway
~167 mo
Low dilution risk
Lead asset
VDPHL01
Phase 3 · Androgenetic Alopecia

Full Press Release Details

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent corporate and clinical progress. “This has been a defining year for Veradermics as we advanced the development of VDPHL01 as a potential treatment for pattern hair loss in both men and wome

Frequently Asked Questions

What is VDPHL01?

VDPHL01 is a late-stage therapeutic candidate developed by Veradermics for treating pattern hair loss in men and women.

What financial period was reported?

The company reported financial results for the third quarter ended September 30, 2026, alongside clinical updates.

Who founded Veradermics?

Veradermics was founded by dermatologists, focusing on innovative therapeutics for dermatological conditions like pattern hair loss.

What clinical progress was made?

The company highlighted recent corporate and clinical progress in advancing VDPHL01 as a potential treatment for pattern hair loss.

ShareAdd on Google
Tags: MANE Veradermics VDPHL01 hair loss biopharmaceutical
Last updated: Nov 10, 2026

Biotech snapshot

Cash runway
$820M liquidity · $5M/mo burn
~167 mo
Low dilution risk
Lead asset
VDPHL01Phase 3
Androgenetic Alopecia →

Catalyst track record

+59%
best trade around MANE's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MANE.

See every catalyst's timing & PoA →